Substituted acyl derivatives of amino acids |
| OF THE INVENTION The invention in its broad aspects includes substituted acyl derivatives of amino ... |
|
Escherichia coliO-polysaccharide-protein conjugate vaccine |
| OF THE INVENTION The present invention relates to E. coli-protein conjugates for use in vaccines ... |
|
Milk production |
| What is claimed is: 1. The method of improving rumen acetate/propionate ratios and milk production ... |
|
Heterocyclic compounds, processes for their preparation and their use |
| We claim: 1. A compound of general formula (I): ##STR14## in which the amide function is in the 2 ... |
|
Virus insecticide compositions |
| What is claimed is: 1. A particulate insecticidal composition comprising a free-flowing particle ... |
|
Stable prostaglandin E group-containing formulation |
| OF THE INVENTION Now, as described above, thiol compounds, water-soluble high molecular weight ... |
|
Medicinal facial mask |
| OF THE INVENTION The compositions of the present invention comprise a pharmaceutically and ... |
|
p75 TNF receptor promoters |
| OF THE INVENTION A human genomic library containing the human p75 TNF-R was obtained from S... |
|
Method of immunizing cats against shedding of Toxoplasma oocysts |
| I claim: 1. A method of immunizing a cat against shedding of Toxoplasma oocysts which comprises the ... |
|
Vaccine for immunizing cats against toxoplasma oocyst shedding |
| What is claimed is: 1. A method of immunizing cats against Toxoplasmosis without concomitant oocyst ... |
|
|
Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli
| Details |
Inventors: Doyle, Michael P.; Zhao, Tong; Harmon, Barry G.; Brown, Cathy Ann;
Assignee: University of Georgia Research Foundation Inc. (Athens, GA)
Primary Examiner: Saucier; Sandra E.
Assistant Examiner: Afremova; Vera
Attorney, Agent or Firm: Greenlee Winner and Sullivan PC
The prevention and treatment of carriage of E. coli O157:H7 by a ruminant animal is accomplished by administering dominant probiotic bacteria to the animal. The dominant probiotic bacteria prevent the establishment of E. coli O157:H7 when inoculated prior to administering E. coli O157:H7, are reisolatable from the gastrointestinal tract of inoculated animals for up to 28 days post-inoculation, and are capable of reducing or eliminating E. coli O157:H7 from animals previously inoculated with the pathogen. In particular, the dominant probiotic bacteria are strains E. coli 271 ATCC 202020, E. coli 786 ATCC 202018 and E. coli 797 ATCC 202019. |
|
DETAILED DESCRIPTION OF THE INVENTION Histologic examination of colonic tissue has revealed no evidence of attachment of E. coli O157:H7 to bovine colonic tissue. The rumen appears to be the most important site for long-term carriage of E. coli O157:H7. The presence of O157:H7 bacteria in the colon is considered to be a transient state, the bacteria passing through from the rumen source and being shed in feces. Animals can be initially infected by ingestion of contaminated grass, feed or water. Results of the present study demonstrate that E. coli O157:H7 persists in the rumens of untreated calves up to 30 days after a single inoculant dose, and is shed in feces throughout the same time period. The O157:H7 bacteria are therefore carried by cattle along with any other microbial strains that inhabit the animals'digestive tract. For purposes of this invention, cattle and other animals in whose tissues or feces E. coli O157:H7 can be detected are said to carry E. coli O157:H7. The amount of E. coli O157:H7 carried by an animal is measurable in various ways, including sampling from various tissues. Most conveniently, the presence of E. coli O157:H7 can be measured in feces. Such measurement is of practical importance, since fecal contamination is the apparent source of meat contamination and also of reintroduction and infection of other animals. As shown herein, the amount of E. coli O157:H7 shed in feces is reflected in the amount measurable in the rumen. Therefore, the amount of E. coli O157:H7 in feces is a measure of the amount carried by the animal. Quantitative measurement of E. coli O157:H7 is expressed as colony forming units (CFU) per g feces or per ml rumen. "Probiotic" is used herein as an adjective to describe bacteria isolated from a natural source and having the property of inhibiting the growth of E. coli O157:H7. The test of an inhibition used herein was an in vitro test on solid medium in which culture supernatants of candidate isolated bacteria were observed for their property of inhibiting E
|
| Related patents |
|
|
Feline leukemia virus vaccines
OF THE INVENTION Any immunogenic FeLV protein may be expressed in baculovirus following the methods and techniques described here. For instance, the location and ...
|
|
|
Resolution of D,L-dehydroproline
I claim: 1. A method for the preparation of L-3,4-dehydroproline comprising in combination the steps of: A. treating N-protected D,L-3,4-dehydroproline with R(+)-alpha-...
|
|
|
Quaternary salts as hypoglycemic agents
OF THE INVENTION The hypoglycemic agents of the present invention are synthesized by the reaction of a suitable halide with the appropriate heterocyclic ring system, ...
|
|
|
7-[.alpha.-(2-Aminomethyl-1-cyclohexenyl)-acetamido]-3-heterocyclic thiomethyl-3-cephem-4-carboxylic acids
We claim: 1. An acid having the formula ##SPC42## wherein R is ##SPC43## ##SPC44## or ##EQU1## or a nontoxic, pharmaceutically acceptable salt thereof. 2. The acid of ...
|
|
|
Pasteurized therapeutically active protein compositions
What is claimed is: 1. A method of pasteurizing a composition comprising a thermally sensitive, therapeutically active protein selected from the group consisiting of ...
|
|
|
Method of preparing a high-purity, virus safe, biologically active transferrin preparation
We claim: 1. A method of preparing a high-purity, virus-safe biologically active, transferrin preparation from plasma fractions that contain transferrin, comprising a) ...
|
|
|
Hydrolyzable resin composition and an antifouling coating composition containing the same
What is claimed is: 1. A method of preventing marine fouling which comprises applying to a surface to be protected from fouling, an anti-fouling hydrolyzable resin ...
|
|
|
Treatment for herpes virus
OF THE INVENTION According to the invention, I provide a composition for and method of use of such composition, for the topic treatment of herpes virus lesions, which ...
|
|
|
Microbicidal meta oxy- and thio-substituted phenylanilines
What is claimed is: 1. A compound of the formula I, including salts and metal complexes thereof ##STR52## wherein R.sub.1 and R.sub.2 independently of one another are ...
|
|
|
Synergistic microbiocidal composition containing a mixture of a bicyclic polyoxymethyleneoxazolidine and an acroloin/formaldehyde polycondensation product
We claim: 1. A microbiocidal composition comprising a synergistic mixture the first component of which is an acrolein/formaldehyde polycondensation product having a ...
|
|
|